DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Application and Claims Status
Claims 47-66 were pending. In the amendment as filed on 8/5/2026, applicants have amended claims 47-64; cancelled claims 65-66; and added no new claims. Therefore, claims 47-64 are currently pending and claims 47-64 are examined herein.
Specification
The objection to the specification (abstract) is withdrawn based on Applicant’s amendments.
Claim Objections
The objections to claims 48-55, 58-61, and 63-66 due to various minor informalities are withdrawn based on Applicant’s amendments.
Claim Rejections - 35 USC § 112(b)
The rejection of claims 64-66 under 35 U.S.C. 112(b) is withdrawn based on Applicant’s amendments. Applicant has removed the phrases: “an SOS1-mediated disease or disorder,” “a disease or disorder caused by the interaction of SOS1 with Ras or SOS1 with Rac,” and “a KRAS-mediated disease or disorder”.
The rejection of claim 65 under 35 U.S.C. 112(b) for lack of antecedent basis is withdrawn based on Applicant’s cancellation of the claim.
Claim Rejections – 35 USC § 112(a)
The rejection of claims 47-66 under 35 U.S.C. 112(a) (Written Description) is withdrawn based on Applicant’s amendments. Specifically, Applicant has removed the term “prodrug” from all claims containing this term.
The rejection of claims 64-66 under 35 U.S.C. § 112(a) (Enablement for Cancer) is withdrawn based on Applicant’s amendments. Specifically, Applicant has amended their claim to recite the short list of enabled cancer, which are “pancreatic cancer, lung cancer, or colorectal cancer”, for which Applicant has provided support in their specification (Table 1, pages 284-286; Table 2, pages 286-287).
The rejection of claims 64-66 under 35 U.S.C. § 112(a) (Enablement for “SOS1 mediated disease or disorder”, etc. generally) is withdrawn based on Applicant’s amendments. Specifically, Applicant has removed the phrases “an SOS1-mediated disease or disorder”, “a disease or disorder caused by the interaction of SOS1 with Ras or SOS1 with Rac”, and “a KRAS-mediated disease or disorder” from claim 64.
The rejection of claims 64-66 under 35 U.S.C. 112(a) (Scope of Enablement – Prevention) is withdrawn based on Applicant’s arguments. Applicant argues that “in the present application, ‘treating/treatment’ and ‘preventing/prevention’ are two independent and mutually exclusive definitions”. This is found persuasive.
Double Patenting
The provisional rejection of claims 47-61, 63-66 on the ground of nonstatutory double patenting as being unpatentable over at least claims 29-30, 45-48 of copending Application No. 18/556,862 is withdrawn because reference claims 29-30, and 45-48 that contained overlapping subject matter have been cancelled from Application No. 18/556,862. The new claims of 18/556,862 do not overlap in subject matter with the claims of the instant application.
The provisional rejection of claims 47-61, 63-66 on the ground of nonstatutory double patenting as being unpatentable over at least claims 1-4, 6-11 of copending Application No. 19/119,798 is maintained because there are still outstanding rejections.
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 47-61, 63-66 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over at least claims 1-4, 6-11 of copending Application No. 19/119,798 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other.
Reference claims 1 and 5 teach a genus and species, respectively, that read on the genus of instant claim 1. Reference claim 1 teaches the following S components:
PNG
media_image1.png
195
145
media_image1.png
Greyscale
PNG
media_image2.png
167
125
media_image2.png
Greyscale
PNG
media_image3.png
174
131
media_image3.png
Greyscale
PNG
media_image4.png
193
150
media_image4.png
Greyscale
; linkers L embraced by the LA notation of instant claim 1; and the following E components, as examples:
PNG
media_image5.png
116
144
media_image5.png
Greyscale
PNG
media_image6.png
101
625
media_image6.png
Greyscale
Further, reference claim 6 teaches a pharmaceutical composition comprising the same, which overlaps in scope with instant claim 63. Reference claims 7-8 teach a method of use in treating an SOS-1 mediated disorder, or a cancer with the reference compounds, which overlaps in scope with instant claim 64. Reference claim 11 teaches a method of use for the treatment of a KRAS-mediated disease, wherein the KRAS mutant is one or more of KRAS G12C, KRAS G12D, GRAS G13D, and GRAS G12V, which reads on instant claims 65-66.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented
New Objections/Rejections
(Not Necessitated by Claim Amendment)
Claim Objections
Claim 47 is objected to because of the following informalities:
In the limitation of R3”, the “1-3 halogens” should be amended to recite either “1 to 3 halogens” or “1, 2, or 3 halogens”. Appropriate correction is required.
The image of S7a’ is blurry and illegible. For instance, what is the R group between the thiophene and aniline NH? Appropriate correction is required.
The word “and” should be between the limitations of R7 an R8 so as to recite “R7 is C1-C6 alkyl; and…”
Claim 50 is objected to because of the following informality: the image of S7a” is blurry and illegible. For instance, what is the letter associated with the substituent of the phenyl bring? Appropriate correction is required.
Claim 54 is objected to because of the following informalities:
The image of LA is blurry and illegible.
After the term “X” is -C(O)-;” and before point (3), the word “or” should be inserted.
The claim recites the following terms with both brackets and underlines: “LA[[-2]]”, “LA[[-3]]”, and “LA[[-4]]”. The combined bracketed and underlined notation makes it unclear if Applicant is trying to remove the bracketed term, or keep the bracketed terms. Appropriate correction is required.
Claim 55 is objected to because of the following informalities:
Again, there is combined bracketed and underlined notation in the claim (e.g. “[[LA-2]](1)”) that needs to be corrected for clarity. Applicant should amend all occurrences. Appropriate correction is required.
At the bottom of page 9, in the definition of L3, Applicant has previously amended the claim to provide strikethroughs for all instances of L3 that contain the k’ and k’’ variable. However, Applicant has missed the following compound, which also needs to be removed with a strikethrough:
PNG
media_image7.png
59
141
media_image7.png
Greyscale
Claim 62 is objected to because of the following informality: commas should be separating each of the claimed species, and additionally, the word “or” should be inserted between the last two species of the claim.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 64 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 64 is rejected as vague and indefinite. The current claim recites “a method for treating a cancer…comprising: administering the compound, or the stereoisomer, the enantiomer, the diastereomer, the deuteride, the hydrate, the solvate, or the pharmaceutically acceptable salt thereof according to claim 47…”. Is Applicant administering any amount (which could be suboptimal and have no therapeutic benefit), or a therapeutically effective amount? Examiner recommends adding a “therapeutically effective amount” into the claim language.
Claim Rejections - 35 USC § 112(a)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 47-53, 55, 58-61, and 63-64 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
This is a written description rejection.
The analysis for adequate written description considers the following:
(a) Actual reduction to practice;
(b) Disclosure of drawings or structural chemical formulas;
(c) Sufficient relevant identifying characteristics, such as (i) complete/partial structure, (ii) physical and/or chemical properties, and (iii) functional characteristics when coupled with known or disclosed correlation with structure; and
(d) Representative number of samples.
A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571,39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967).
An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.
In particular, the specification as originally filed fails to provide sufficient written description on the bases of any of the agents demonstrating wherein possession of use of the following formula of LA of claim 47:
PNG
media_image8.png
105
300
media_image8.png
Greyscale
Claim 47 recites Formula I comprising a vast variety of subgenus alternatives of binding moiety linker, degron moieties, and/or combination thereof, wherein the Markush grouping embraces different chemical species that do not belong to the same recognized chemical class and/or do not share substantial structural similarity. It is noted ring A, B, C, X’’, X’’’, L3, could be a bond or variety of groups, e.g. S(O), S(O2)-, etc. such that instant claimed LA moiety:
PNG
media_image8.png
105
300
media_image8.png
Greyscale
,
comprising combinations of ring A, B, C, X’’, X’’’ and L3 do not share substantial structural similarity.
Instant claims 47-53, 55, 58-61, and 63-64 recite linker moiety comprising variety of subgroups further substituted with different groups and combination thereof, wherein the combination of linker groups do not belong to the same recognized chemical class and/or share substantial structural feature, e.g.
PNG
media_image9.png
125
261
media_image9.png
Greyscale
,
PNG
media_image10.png
140
278
media_image10.png
Greyscale
.
The claims lack written description because the genus of LA has substantial variance while the specification lacks sufficient variety of species to reflect the variance within the genus, and because of the lack of common structural attributes of the claimed genus, combined with a correlation between structure and function. Since there is only minimal structure similarity to the Markush alternative of compounds of Formula I, one can conclude that the instantly claimed compounds are substantially structurally different. Further, there is no common use that flows from the shared structure features. Instant claimed compound species exhibit variety of inhibitory activity in 3D cell proliferation assay of different KRAS mutant human cell, ranging from <=50 nM to >=100 nM, to not detected (See instant Table 1, pages 284-286), which further attest common use is not fully established from the shared minimal common structure.
The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.
A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."
Thus, claims 47-53, 55, 58-61, and 63-64 are rejected under 35 USC 112(a), (Written Description).
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 47-64 are rejected under 35 U.S.C. 103 as being unpatentable over Chan et al. (WO 2022/061348 A1, published March 24, 2022, effectively filed September 16, 2020, cited on IDS filed 2/12/2024)(hereinafter, ‘Chan’) in view of Arista et al. (WO 2021053495 A1, published March 25, 2021)(hereinafter, ‘Arista’).
Regarding bifunctional degrader targeting at SOS1 protein (son of sevenless homolog 1), Chan teaches compound of Formula I to XV, or an enantiomer, solvate, hydrate, pharmaceutically acceptable salt thereof and pharmaceutical composition thereof, comprising SOS1 protein binding moiety, linker moiety (L) and ubiquitin ligase-binding moiety RE, as modulators of SOS1 protein through SOS1 degradation/inhibition for treating disease/disorder mediated by SOS1 or Ras (e.g. cancer, etc.) (See abstract; page 2, [0007]-[0082], [00110], Examples A1 to A70, claims 1-159).
PNG
media_image11.png
131
249
media_image11.png
Greyscale
PNG
media_image12.png
247
718
media_image12.png
Greyscale
Regarding instantly claimed SOS1 binding moiety as recited in instant claims 47-51, Chan teaches a variety of embodiments as SOS1 binding moieties (See [00110]-[00116]):
PNG
media_image13.png
157
246
media_image13.png
Greyscale
PNG
media_image14.png
140
241
media_image14.png
Greyscale
PNG
media_image15.png
141
253
media_image15.png
Greyscale
PNG
media_image16.png
164
254
media_image16.png
Greyscale
Of particular note, Formula XXIV-c of Chan reads on the S moiety of instant claims.
Regarding linker moieties recited in instant claims 47, 52-57, Chan teaches embodiments comprising a variety of linker groups and combinations thereof (See [0275]-[00305]):
PNG
media_image17.png
415
736
media_image17.png
Greyscale
Of particular note, RL of Chan reads on instant L3 and rings A, B, and C; and ZL of Chan reads on X” and X’” of instant claims.
Furthermore, Chan teaches embodiments comprising 3,9-diazaspiro[5.5]undecane
PNG
media_image18.png
92
131
media_image18.png
Greyscale
,
PNG
media_image19.png
76
106
media_image19.png
Greyscale
,
PNG
media_image20.png
72
60
media_image20.png
Greyscale
,
PNG
media_image21.png
91
148
media_image21.png
Greyscale
, etc. that read on instant recited ring A, B, C, and combination thereof, e.g.
PNG
media_image22.png
79
176
media_image22.png
Greyscale
,
PNG
media_image23.png
103
182
media_image23.png
Greyscale
(See [00297]-[00298], [00302]-[00305]).
Regarding the small molecule ligand of an E3 ubiquitin ligase complex and instant claims 58-61, Chan teaches embodiments comprising variety of RE as CRBN E3 binding moiety, e.g. EC-I, EC-II, etc. (See [00120]-[00123], [00159], [00165]):
PNG
media_image24.png
124
325
media_image24.png
Greyscale
PNG
media_image25.png
133
197
media_image25.png
Greyscale
PNG
media_image26.png
123
204
media_image26.png
Greyscale
.
Regarding claim 62, Chan teaches bifunctional compound species comprising SOS1 binding moiety and linker moiety that are similar to instant claimed moiety, e.g. A15, A16, A19, etc.
PNG
media_image27.png
215
560
media_image27.png
Greyscale
PNG
media_image28.png
205
557
media_image28.png
Greyscale
PNG
media_image29.png
216
513
media_image29.png
Greyscale
Regarding claim 63, Chan teaches pharmaceutical composition comprising compound of formula I and a pharmaceutically acceptable excipient (See [0008],[00320], claims 141-145).
Regarding claim 64, Chan teaches a method of treating cancer (claims 150-154).
The difference between the compounds of Chan and the instantly claimed compounds is the combination of linker moiety and the ubiquitin ligase-binding moiety.
Arista teaches bifunctional compound of Formula I, or pharmaceutically acceptable salt thereof, comprising various protein binding moiety, linker moiety (L) and ubiquitin ligase-binding moiety for treating disease/disorder mediated by various target proteins (e.g. cancer, etc.) (See abstract; page 2, lines 11-26; claims 1-209):
PNG
media_image30.png
73
619
media_image30.png
Greyscale
.
Arista teaches variety of Targeting Ligase Binder, e.g. TLB-I to TLB-IX, etc. (See page 2, line 22 to page 8, lines 1-13):
PNG
media_image31.png
159
318
media_image31.png
Greyscale
PNG
media_image32.png
152
269
media_image32.png
Greyscale
PNG
media_image33.png
181
811
media_image33.png
Greyscale
Of particular note, ligase binder TLB-IX, wherein Rd6 is H, halogen, C1-6 alkyl, C1-6 alkoxyl, etc. reads on instant E moiety recited in instant claims 58-61.
Arista teaches a variety of linker moieties (See page 8, lines 14 to 27):
PNG
media_image34.png
70
264
media_image34.png
Greyscale
PNG
media_image35.png
338
824
media_image35.png
Greyscale
PNG
media_image36.png
178
818
media_image36.png
Greyscale
Arista teaches linker moiety that are similar to instantly claimed linker moiety (See page 9, lines 10-17):
PNG
media_image37.png
170
71
media_image37.png
Greyscale
PNG
media_image38.png
95
196
media_image38.png
Greyscale
PNG
media_image39.png
88
240
media_image39.png
Greyscale
..
Arista also teaches Targeting Ligase Binder-Linker, e.g. TLB-L-I to TLB-L-IX (See page 10, lines 17-22 to page 24, lines 1-10):
PNG
media_image40.png
177
483
media_image40.png
Greyscale
PNG
media_image41.png
159
454
media_image41.png
Greyscale
PNG
media_image42.png
200
519
media_image42.png
Greyscale
(See page 28, line 5).
Arista teaches various embodiments comprising targeting ligase binder-Linker that read on instant E moiety and very similar to instant linker moiety (See page 301, 302, etc.):
PNG
media_image43.png
174
314
media_image43.png
Greyscale
PNG
media_image44.png
175
293
media_image44.png
Greyscale
.
Arista teaches bifunctional compound BF-IV, BF-V-A, BF-V-B, etc. comprising the targeting ligand, the linker moiety, and the targeting ligase binder (See page 29, lines 3-23; page 30, lines 12-22; page 31, lines 1-26):
PNG
media_image45.png
370
664
media_image45.png
Greyscale
PNG
media_image46.png
247
378
media_image46.png
Greyscale
Arista teaches various targeting ligand, e.g. ARAF, BRAF, KRAS, KRAS G12V/C/D etc. (See Table 1 starting from page 34). It is noted the targeting ligand KRAS read on instant SOS1 which is associated/interacted with KRAS pathway.
It would have been prima facie obvious to one of ordinary skilled in the art before the effective filing date of instant application to explore more SOS1 modulator/inhibitor comprising SOS1 binding moiety, linker moiety, and ULM moiety, based on the combined teachings of Chan and Arista, together with optimization based on general knowledge of structure similarity and bioisosteric modification for SAR study of bifunctional degraders, in order to arrive at instantly claimed invention with reasonable expectation of success. At the time the instant invention was made, it was already known that bifunctional SOS1 modulator comprising SOS binding moiety, linker moiety, ULM moiety targeting at SOS1 degradation, e.g.
PNG
media_image16.png
164
254
media_image16.png
Greyscale
could be made, as taught by Chan. Arista further teaches variety of ubiquitin binding moiety, linker groups and combination thereof, e.g.
PNG
media_image44.png
175
293
media_image44.png
Greyscale
,
PNG
media_image43.png
174
314
media_image43.png
Greyscale
that could combine with various targeting ligand, including KRAS that is associated with SOS1.
According to M.P.E.P. § 2144.09, a prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). A skilled artisan would be motivated to further explore more bifunctional SOS1 modulators based on combined teachings of Chan and Arista, and reasonably expect further exploration/optimization together with general knowledge of structure similarity and bioisosteric modification would provide more alternative bifunctional compounds as SOS1/KRAS modulator. The exploration of different linker moiety and attachment for the targeting ligand moiety and ULM moiety based on general knowledge of structural similarity and bioisosteric modification are within the knowledge of ordinary skilled in the art as illustrated in Chan and Arista.
One of ordinary skill in the art would have had reasonable expectation of success in producing the claimed invention based on the combined teachings of prior art and general knowledge of structure similarity/bioisosteric modification and proteasome-mediated degradation of targeting protein. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary.
Conclusion
All claims are rejected.
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUKE ALAN BORALSKY whose telephone number is (571)272-9746. The examiner can normally be reached Monday - Friday 7:30 am - 5:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/L.A.B./Examiner, Art Unit 1624
/SUSANNA MOORE/Primary Examiner, Art Unit 1624